| 货号 | HB895036 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 宿主 | Human |
|---|
| 同种型 | VHH-His |
|---|
| 克隆号 | GSK1995057 |
|---|
| 生物活性 | GSK1995057 (10 nM; 12 h) significantly inhibits LPS ()-induced loss of cell viability in human nucleus pulposus cells, and attenuates cell apoptosis by regulating proteins of the extrinsic apoptotic pathway [2]. GSK1995057 (10 nM; 12 h) significantly inhibits LPS-induced secretion of pro-inflammatory and regulatory cytokines (IL-1β, IL-6, IL-10, TNF-α), suppresses the upregulated expression of extracellular matrix degrading enzyme genes (MMP-1, MMP-3, MMP-13, ADAMTS-4, ADAMTS-5), and blocks the activation of NF-κB, JNK and P38 MAPK signaling pathways in human nucleus pulposus cells [2]. GSK1995057 (10 nM; 1-4 h) potently inhibits TNF-α-stimulated neutrophil-endothelial cell interactions, endothelial permeability, adhesion molecule expression, and proinflammatory cytokine release in human lung microvascular endothelial cells (HMVEC-L) and human neutrophils [3]. GSK1995057 (0.00001-1 uM; 1 h serum incubation, 24 h cell incubation), upon binding to serum from anti-HAVH antibody-positive donors, activates TNFR1 and induces IL-8 release from MRC-5 human lung fibroblasts, human alveolar epithelial cells, and human primary lung fibroblasts in a concentration-dependent bell-shaped manner [4]. GSK1995057 binds with high affinity (1.65×10 -10 M) to purified polyclonal HAVH autoantibodies [4]. GSK1995057 (0.00001-1 uM) induces TNF-R1 activation and IL-8 release in the human lung fibroblast cell line MRC-5 when mixed with human serum samples containing the co-existing specific autoantibodies against GSK2862277, with the activation effect peaking at 0.001 uM [5]. |
|---|
| 表达系统 | Mammalian cells |
|---|
| 克隆类型 | Monoclonal |
|---|
| 靶标 | TNFR-I, Tumor necrosis factor receptor 1, Tumor necrosis factor receptor superfamily member 1A, TBPI, p60, CD120a, TNFRSF1A, Tumor necrosis factor receptor type I, p55, TNF-RI, TNFAR, TNFR1, TNF-R1 |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Purified by Nickel column |
|---|
| Accession号 | P19438 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 产品使用信息 |
| 应用方法 |
稀释比例 |
| ELISA |
1:2000-1:20000 |
|
|---|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | GSK1995057 |
|---|
| 背景 | Tumor necrosis factor receptor superfamily member 1A (CD120a/TNFR1) is a ~50 kDa protein. Receptor for TNFSF2/TNF and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase. |
|---|
| 文献 | 1. Liao K, et al. Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naïve Subjects. AAPS J. 2018;20(3):51. Published 2018 Mar 16. [HB895036]
2. Lv F, et al. Inhibition of TNFR1 Attenuates LPS Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Regulating the NF-KB and MAPK Signalling Pathway. Neurochem Res. 2021;46(6):1390-1399. [HB895036]
3. Proudfoot A, et al. Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury. Thorax. 2018;73(8):723-730. [HB895036]
4. Holland MC, et al. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol. 2013;33(7):1192-1203. [HB895036]
5. Cordy JC, et al. Specificity of human anti-variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1. Clin Exp Immunol. 2015;182(2):139-148. View More [HB895036] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
